CervoMed Inc., a clinical-stage biotechnology company developing treatments for age-related brain disorders, will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The event is scheduled to take place virtually on Monday, June 15, 2026. This engagement provides investors with an opportunity to hear directly from management about the company's strategic direction and clinical progress.

Presentation Details

The fireside chat is set to occur from 7:00 AM to 7:30 AM ET. Investors can access the live webcast through a specific link provided for the event. Additionally, a recording of the session will be made available in the Investor section of the CervoMed website following the presentation.

Clinical Pipeline Overview

CervoMed's lead drug candidate, neflamapimod, is an oral small molecule designed to inhibit a key enzyme involved in neuroinflammation and neurodegeneration. The company recently completed the Phase 2b RewinD-LB trial evaluating neflamapimod in patients with Dementia with Lewy Bodies (DLB). In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, though the initiation of a Phase 3 trial is subject to securing a partnership or additional financing.

Upcoming Milestones

The company has also completed enrollment in its ongoing Phase 2a clinical trial for neflamapimod in non-fluent variant primary progressive aphasia (nfvPPA), a subtype of frontotemporal disorders. Interim biomarker data from this trial is anticipated in the early fourth quarter of 2026. Furthermore, CervoMed expects the first patient to be dosed in the EXPERTS-ALS Phase 2a clinical trial during the fourth quarter of 2026.

CervoMed Inc. has entered into a definitive securities purchase agreement for a private placement expected to generate upfront gross proceeds of approximately $10.5 million. The financing, led by institutional healthcare investors and supported by insiders including Board Chair Joshua S. Boger, PhD, and President and CEO John J. Alam, MD, extends the company's anticipated cash runway into the second quarter of 2027. The capital injection is intended to support the pursuit of a strategic partnership to advance neflamapimod into Phase 3 development for the treatment of dementia with Lewy bodies (DLB).

The company's strategic priority is to establish a partnership to fund the later-stage clinical trials required for the drug's development. Neflamapimod is currently being evaluated for its efficacy in treating neurodegenerative diseases. CervoMed has achieved alignment with the US Food and Drug Administration (FDA) on a potential registration path for DLB, announced in November 2025, and with the Medicines Healthcare products Regulatory Agency in the United Kingdom and the European Medicines Agency in January 2026.

Anticipated pipeline milestones over the next six months include obtaining 24-week biomarker and clinical data from a Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA). Additionally, the company plans to initiate the EXPERTS-ALS Phase 2a trial, with the first patient dosing anticipated in the fourth quarter of 2026. These milestones are expected to provide key data points to support further development and potential partnership discussions.

The private placement involves the sale of 3,360,377 units. Each unit consists of one share of common stock or one pre-funded warrant, one Series B warrant, and one Series C warrant. The purchase price per unit is $3.14 for common stock units and $3.139 for pre-funded warrant units. The Series B warrants expire on June 11, 2031, while the Series C warrants expire on June 11, 2027. The transaction is expected to close on or about June 11, 2026.

The participation of insiders and institutional investors underscores confidence in CervoMed's pipeline and strategic direction. The secured funds provide the necessary resources to achieve these near-term clinical goals without immediate dilution from other financing methods. The company intends to use the net proceeds to fund research and development of neflamapimod, working capital, and general corporate purposes.